MAI Capital Management’s Apogee Therapeutics APGE Stock Holding History

MAI Capital Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6	Closed	-$506	–	2232
2026 Q1	$506	Buy	+6	New	+$436	﹤0.01%	4412

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

MAI Capital Management's APGE Position: Q2 2026 in Review

MAI Capital Management sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 6 shares — an estimated $506 sold.

MAI Capital Management first reported a position in APGE in Q1 2026 and held it in 1 quarter. The position peaked at $506 in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

MAI Capital Management reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 6 Apogee Therapeutics shares in Q2 2026, an estimated $506.
MAI Capital Management first reported a position in Apogee Therapeutics in Q1 2026 and held it in 1 quarter.
MAI Capital Management's Apogee Therapeutics position peaked at $506 in Q1 2026.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.